Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Alexandra MacLean
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
development of intravenous Tramadol
|
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:Miami,_Florida,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avenue Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:NASDAQ_Capital_Market
|
| gptkbp:parentCompany |
gptkb:Fortress_Biotech
|
| gptkbp:product |
IV Tramadol
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ
|
| gptkbp:status |
clinical-stage
|
| gptkbp:stockSymbol |
ATXI
|
| gptkbp:website |
https://www.avenuetx.com/
|
| gptkbp:bfsParent |
gptkb:Fortress_Biotech
|
| gptkbp:bfsLayer |
7
|